A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

Key Inclusion Criteria:

1. Is a male or female aged 55 to 90 years, inclusive, at Screening.

2. Can understand the nature of the trial and protocol requirements and provideinformed consent or assent before any study assessments are performed.

3. Meets clinical criteria for Possible AD or Probable AD.

4. Living at the same home or residential assisted-living facility for a minimum of 6weeks before Screening.

5. Have an identified study partner who should have daily contact (approximately 10hours a week or more).

6. History of psychotic symptoms (meeting International Psychogeriatric Associationcriteria) (Cummings 2020) for at least 2 months prior to Screening.

7. CGI-S scale with a score ≥ 4 at Screening and Baseline.

8. AD subjects are required to have NPI-C: Hallucinations and Delusions (H+D) score of ≥ 6 AND meet at least 1 of the following criteria at Screening and Baseline:

9. Moderate to severe delusions, defined as NPI-C: Delusions domain score of ≥ 2on 2 of the 8 items OR

10. Moderate to severe hallucinations, defined as NPI-C: Hallucinations domainscore of ≥ 2 on 2 of the 7 items

11. MMSE score of 8 to 22, inclusive, at Screening.

Key Exclusion Criteria:

1. Psychotic symptoms that are primarily attributable to a condition other than the ADcausing the dementia.

2. History of major depressive episode with psychotic features during the 12 monthsprior to Screening.

3. History of bipolar disorder, schizophrenia, or schizoaffective disorder.

4. Significant or severe medical conditions including pulmonary, hepatic, renal,hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic,cardiovascular, or oncologic disease or any other condition that, in the opinion ofthe Investigator, could jeopardize the safety of the subject, ability to complete orcomply with the study procedures or validity of the study results.

5. History or high risk of urinary retention, gastric retention, or narrow-angleglaucoma as evaluated by the Investigator.

6. Prior exposure to KarXT.

7. History of hypersensitivity to KarXT excipients or trospium chloride.

8. Experienced any significant adverse events (AEs) due to trospium.

9. Participation in another clinical study in which the subject received anexperimental or investigational drug within 3 months before Screening or hasparticipated in more than 2 clinical studies in the 12 months prior to Screening.